The trial's success stems from its pragmatic design, which broadly included any cancer patient who smoked recently, regardless of their motivation to quit. This contrasts with traditional trials that select highly motivated volunteers, making these findings more applicable to typical, diverse patient populations in real-world cancer care.

An analysis of EMERALD and LEAP trial criteria against real-world HCC cases reveals that a majority of complex patients (e.g., multifocal, large tumors) who could most benefit from combination therapies were ineligible, cautioning clinicians against broad application of trial results.

The LIDERA trial's success is complicated because it was designed against a standard of care that is now outdated. It excluded CDK4/6 inhibitors, which are now common for high-risk patients, creating a gap in understanding how to integrate this new drug into modern clinical practice.

The LEAP-010 trial excluded patients with vascular involvement due to the drug's bleeding risk. This is a common characteristic in real-world head and neck cancer patients, especially post-radiation. This discrepancy means that even if the drug combination had been successful, its applicability in routine clinical practice would be severely limited.

The traditional drug-centric trial model is failing. The next evolution is trials designed to validate the *decision-making process* itself, using platforms to assign the best therapy to heterogeneous patient groups, rather than testing one drug on a narrow population.

A common failure in biotech is viewing patients solely as data sources rather than as human partners in the development process. This perspective leads to unnecessarily complex protocols with high patient burden. The most successful firms build relationships with patient advocacy groups and design trials that respect the patient's experience.

Despite statistically significant results, Akiso's successful China-only study faced skepticism due to its trial design. Exclusions of older patients and those with high bleeding risk cast doubt on whether the positive findings can be replicated in a diverse global population, posing a barrier to wider acceptance.

Even when trials like LITESPARK 022 and Keynote 564 use identical eligibility criteria, outdated staging systems result in patient populations with different underlying risks. This makes direct comparison of outcomes between trials, even for the same drug, an unfair and statistically flawed analysis that ignores the function of a control arm.

Strict, and sometimes arbitrary, clinical trial eligibility criteria are a key barrier to enrollment. A patient with a GFR of 52 being excluded from a trial requiring a GFR of 60 illustrates how minor, clinically insignificant differences can prevent patients from accessing novel therapies. This highlights a need for more pragmatic and flexible trial inclusion criteria.